Neuroscience Antibodies & Assays Global Market Report 2024

Neuroscience antibodies and assays play a crucial role in examining the development, systems, structure, function, disorders, and degeneration of the nervous system. Neuroscience, as a field, focuses on understanding the nervous system, its functioning, and disorders associated with it. Antibodies and assays, which are medical tests based on the interaction between antigenic epitopes and antibodies, find significant utility in neuroscience and the investigation of neurological disorders.

The primary categories of products in the neuroscience antibodies and assays market include consumables and instruments. Consumables, essential in numerous neurological studies and research experiments, comprise assay kits, reagents, and antibodies, facilitating quantitative and real-time live-cell analysis. Technologies employed in this domain encompass molecular diagnostics, clinical chemistry, immunoassays or immunochemistry, and other relevant technologies. Applications of neuroscience antibodies and assays span in vitro diagnostics, research, and drug discovery. The end users of these products are diverse, including hospitals and diagnostics centers, academic and research institutes, as well as pharmaceutical and biotechnology companies.

The neuroscience antibodies & assays market research report is one of a series of new reports that provides neuroscience antibodies & assays market statistics, including neuroscience antibodies & assays industry global market size, regional shares, competitors with an neuroscience antibodies & assays market share, detailed neuroscience antibodies & assays market segments, market trends and opportunities, and any further data you may need to thrive in the neuroscience antibodies & assays industry. This neuroscience antibodies & assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuroscience antibodies & assays market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The growth observed in the historical period can be attributed to several factors, including research funding, the processes of drug discovery and development, the prevalence of neurodegenerative diseases, government initiatives, and the advancement of personalized medicine.

The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $7.68 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The anticipated growth in the forecast period can be linked to various factors, including collaborative efforts, the integration of telemedicine in neurology, advancements in education and training, the development of biomarker-driven therapies, and a heightened focus on neuroimmunology. Significant trends expected in this forecast period encompass the utilization of microRNA and non-coding RNA assays, the adoption of digital pathology, the development of advanced imaging-compatible assays, the application of single-cell analysis, and the emergence of 3D organoid models.

The anticipated increase in the occurrence of neurological illnesses worldwide is expected to drive the growth of the neuroscience antibodies & assays market. Neurological illnesses encompass disorders affecting the nervous system, including conditions such as epilepsy, Alzheimer’s disease, and dementia. The growing prevalence of neurological disorders necessitates increased research and development efforts for effective treatment. Antibodies and assays play a crucial role in these research activities, aiding in the study of the nervous system's development, structure, function, and disorders. For instance, the World Health Organization reports that globally, 55 million people live with dementia, with nearly 10 million new cases reported annually as of 2021. In the United States, according to the Alzheimer's Association, 6.5 million people had Alzheimer's disease in 2022. Therefore, the rising incidence of neurological illnesses worldwide is a key driver propelling the neuroscience antibodies and assays market.

The growth of the neuroscience antibodies & assays market is expected to be fueled by the expanding healthcare sector. The healthcare sector, encompassing various organizations, professionals, and resources dedicated to providing medical services and products, relies extensively on neuroscience antibodies and assays. These tools are crucial for detecting and measuring specific proteins, biomarkers, and molecular processes in the nervous system. Notably, the global healthcare sector experienced growth, returning +19.8% in 2021, according to BlackRock Inc. Consequently, the increasing prominence of the healthcare sector is anticipated to drive the growth of the neuroscience antibodies & assays market.

A notable trend in the neuroscience antibodies and assays market is the adoption of technological advancements. Major market players are introducing innovative technologies, such as NeuroNexus Summa Framework, to enhance their market position. NeuroNexus Technologies, in February 2022, launched the Summa Framework technology, designed to facilitate electrical signal read-outs from biological cells and tissues for both experienced electrophysiologists and life science researchers. This technological advancement is contributing to the development and sustainability of the neuroscience antibodies and assays market.

Major companies operating in the neuroscience antibodies and assays market are focusing on developing innovative products. Product innovation involves a heightened emphasis on creating novel and advanced products to support neuroscience research and diagnostics. For instance, Labcorp, in July 2022, introduced the Neurofilament Light Chain (NFL) blood test, enabling physicians to detect and confirm indicators of neurodegenerative diseases. This test enhances diagnostic capabilities, potentially improving the diagnosis, treatment, and management of neurological disorders.

In June 2022, Fujirebio, a multinational biotechnology company based in Japan, acquired ADx NeuroSciences to expand its global offering of neurodegenerative disease diagnostic solutions. ADx Neurosciences, based in Belgium, specializes in developing tailor-made antibodies and assays for pharma and in vitro diagnostics companies.

Major companies operating in the neuroscience antibodies & assays market include Abcam PLC, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB

North America was the largest region in the neuroscience antibodies & assays market in 2023. The regions covered in neuroscience antibodies & assays market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the neuroscience antibodies & assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The neuroscience antibodies & assays market consists of sales of antibodies and assay kits and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.